TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum MĂĽnchen for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.

About TherVacB

For Patients

TherVacB Team


Partners
European countries
Project duration (months)
Recording available – Introducing the European HBV Patient Registry, HBV Cure Research Community Webinar 101 features, 24/11/2021
Recording available! Online discussion for the HBV community on scientific progress in Europe towards a cure featured TherVacB's European HBV Patient Registry On 24th November 2021 the International Coalition for the Elimination of HBV, ICE-HBV, in partnership with...
Let’s Talk About Ethics in Clinical Research – A FREE Session on Privacy Concerns in Social Media Patient Recruitment, 24.11.2022
An online lecture explores ethical benefits and challenges of social media recruitment for clinical studies. Recruiting patients for clinical studies through social media yields ethical benefits and challenges. On 24th November 2022 at 15:00 CET, TherVacB experts in...
Happy World Hepatitis Day 2022!
Globally, 325 million people live with hepatitis, one of the most neglected diseases. On World Hepatitis Day 2022, the TherVacB project coordinator, Prof. Ulrike Protzer, joins the collective voices from across the world to raise awareness about Hepatitis B (HBV) and...
Animation movie
Enjoy our animation movie to understand the mission and approach of the TherVacB project!
TherVacB Publications
Find here scientific publications and technical articles from TherVacB project partners.
Read more about chronic hepatitis B, the virus, screening and testing for hepatitis C and B, therapeutic vaccination, and cure research.
All you need to know to understand Hepatitis B cure research – The HBV Cure FAQs
Watch the growing collection of short videos answering key questions on cure research raised by people living with Hepatitis B (HBV). The collection is a product of an international consortium of organizations, expert institutions and research projects working in and around Hepatitis B. Actively involved are ICE-HBV, Hepatitis B Foundation, World Hepatitis Alliance, HepBCommunity.org, Australian Centre for Hepatitis Virology, IP-cure-B, the Canadian HBV Network and TherVacB.